Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Standard BioTools Inc. reports developments in life-science research tools built around proprietary mass cytometry and microfluidics technologies. The company sells instruments, consumables and services for genomics, single-cell proteomics and spatial proteomics, including platforms such as Biomark X9, CyTOF XT and Hyperion systems used in research workflows.
Recurring news includes operating and financial results, capital-structure updates, shareholder voting and governance matters, portfolio actions following the completed sale of SomaLogic assets, and collaborations that expand imaging mass cytometry and multi-omic research applications. Company updates also describe translational and clinical research use cases in oncology, immunology and immunotherapy, with products positioned for research use rather than diagnostic procedures.
Standard BioTools (NASDAQ: LAB) announced several developments tied to its pending merger with Treeline Biosciences. The company agreed to sell its Mass Cytometry business, including the CyTOF and Hyperion product lines, to Multiplex Bio, a new entity led by advanced imaging industry veterans. The transaction is valued at up to $10 million, consisting of a seller’s note and a potential milestone payment, and Standard BioTools will provide a working capital loan of up to $10 million at closing. Separately, Standard BioTools received approximately $30 million from Illumina in a negotiated buyout of the 2026 earnout and all accrued and unpaid royalties related to Illumina’s prior acquisition of the SomaLogic business. This cash will be included in Standard BioTools’ pro forma net cash position used in the Treeline exchange ratio. The company also reported early termination of the Hart-Scott-Rodino waiting period and expects the Treeline merger to close by year-end 2026, subject to stockholder approval and customary conditions.
Standard BioTools (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. market close. The company develops standardized next-generation life science tools for biomedical research, provided for research use only and not for diagnostic procedures.
Standard BioTools (NASDAQ: LAB) filed a Form S-4 registration statement with the SEC for its previously announced all-stock merger with Treeline Biosciences. Closing is expected in the second half of 2026, after which the combined company will be named Treeline Biosciences Holdings and trade on Nasdaq as TRLN.
The filing highlights Treeline’s discovery organization and pipeline, including TLN-121, TLN-254, TLN-372 and TLN-499. Initial Phase 1 monotherapy data for TLN-121 in relapsed/refractory lymphomas showed an 84% overall response rate and 32% complete response rate (19 patients), with no dose-limiting toxicities and mostly Grade 1 adverse events. According to Standard BioTools, interim data readouts for TLN-121 and TLN-372 are planned for 2027.
The combined company is expected to have over $900 million in pro-forma cash at closing, which is expected to fund operations and Treeline’s development pipeline into 2029. Treeline has previously raised about $1.2 billion. Treeline also added industry leader Sue Desmond-Hellmann to its Board of Directors.
Standard BioTools (NASDAQ: LAB) and Treeline Biosciences agreed to an all-stock merger, creating a publicly traded company named Treeline Biosciences expected to list on Nasdaq as TRLN in 2H 2026.
The combined company should have over $900 million pro-forma cash, adding about $450 million from Standard BioTools, funding operations into 2029 and advancing Treeline’s pipeline of three Phase 1 programs plus multiple planned clinical entrants through 2028.
Pre-merger Standard BioTools holders are expected to own about 16% and receive a CVR tied to potential proceeds from legacy Mass Cytometry, Microfluidics and Illumina-related earnouts.
Standard BioTools (NASDAQ: LAB) reported first quarter 2026 continuing‑operations revenue of $21.1 million, up 5% year‑over‑year, with gross margin ~53.5% and non‑GAAP gross margin ~57.7%. Adjusted EBITDA was a loss of $3.1 million (78% improvement YoY). Cash and investments were $523.6 million at quarter end, and the company reiterated 2026 revenue guidance of $80–$85 million.
Operating expenses fell 37% to $23.8 million, including $3.1 million of restructuring charges; consumables revenue grew 35% to $11.0 million.
Standard BioTools (NASDAQ: LAB) will report its first quarter 2026 financial results on May 5, 2026, to be released after the U.S. market close.
Investors can expect a post-close release and likely an accompanying conference call or investor materials referenced by the company.
Standard BioTools (NASDAQ: LAB) reported fourth-quarter continuing-operations revenue of $23.8M and full-year 2025 revenue of $85.3M. The company said it fully operationalized over $40M of annualized cost savings, exited the year with meaningfully lower run-rate expenses, and held approximately $550M in cash and investments following the SomaLogic closing.
Gross margin improved to 49.9% for 2025; net loss narrowed to $58.8M. Management expects 2026 revenue of $80M–$85M and noted about $1B in US NOL carryforwards.
Standard BioTools (NASDAQ: LAB) will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
Investors can expect a post-close release and likely an associated investor webcast or call timing to be announced separately by the company.
Standard BioTools (NASDAQ: LAB) completed the sale of SomaLogic to Illumina for $350 million upfront and is eligible for up to $75 million in near-term earnouts, for aggregate cash consideration of up to $425 million plus specified royalties.
As of Jan. 30, 2026, the company estimates approximately $550 million in cash and cash equivalents (unaudited), expects continuing operations to reach positive adjusted EBITDA in 2026, and retains a 2% royalty plus a co-exclusive Single SOMAmer license.
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue for Q4 and full year 2025. The company expects Q4 2025 combined revenue of ~$56 million and revenue from continuing operations of ~$24 million. For full year 2025, it expects combined company revenue of ~$185 million and revenue from continuing operations of ~$85 million. Management said operational cost actions improved the operating model and moved the base business toward positive adjusted EBITDA. The sale of SomaLogic to Illumina is expected to close in H1 2026, and the company expects to have approximately $550 million in cash at close. Final audited results and 2026 outlook will be released later this quarter.